In parallel, network pharmacology analysis identified the top 10 hub genes, which included TP53, AKT1, IL6, STAT3, IL1B, EGFR, TNF, JUN, MYC, and BCL2, highlighting their central roles in GC pathogenesis and potential as therapeutic targets. This evidence concerns the gene EGFR and gastric cancer.